USE OF A HIGH-ADCC ANTI-CD20 ANTIBODY FOR TREATING WALDENSTRÖM'S MACROGLOBULEMIA

摘要

The present application relates to a monoclonal antibody against the CD20 antigen, said antibody having an antibody-dependent cell-mediated cytotoxicity (ADCC) and/or a capability of activating the enhanced effector cells expressing FcyRIII, and having an Fc area at least 60% of the oligosaccarides of which are non-fucosylated oligosaccarides, for the use thereof in treating Waldenström's disease.